胆道系统恶性肿瘤免疫检查点抑制剂治疗  

Immune checkpoint inhibitors for treatment of biliary malignant tumors

作　　者：施国明 裴晏梓 陆品相 曹军 周俭 樊嘉 SHI Guoming;PEI Yanzhi;LU Pinxiang;CAO Jun;ZHOU Jian;FAN Jia(Department of Liver Surgery and Transplantation,Zhongshan Hospital,Fudan University,Shanghai 200032,China;Department of General Surgery,Xuhui District Central Hospital,Shanghai 200032,China;Department of Interventional Oncology,Dahua Hospital,Xuhui District,Shanghai 200032,China)

机构地区：[1]复旦大学附属中山医院肝肿瘤外科,上海200032 [2]上海徐汇中心医院普通外科,上海200032 [3]上海徐汇区大华医院介入肿瘤科,上海200032

出　　处：《临床肝胆病杂志》2022年第5期998-1001,共4页Journal of Clinical Hepatology

基　　金：申康三年计划重大疾病多中心临床研究项目(SHDC2020CR1003A);徐汇区重大攻关项目(XHLHGG202103)。

摘　　要：胆道系统恶性肿瘤起病隐匿、发展迅速,大多患者初诊时已丧失手术根治机会,预后不良。以吉西他滨为基础的化疗是胆道系统恶性肿瘤的一线治疗,但效果有限。二代测序技术的进步为胆道系统恶性肿瘤精准治疗提供了可能性,但靶点阳性率低及治疗药物可及性差限制了胆道系统恶性肿瘤精准治疗的应用和发展。以免疫检查点抑制剂程序性死亡受体及其配体单抗为代表的免疫治疗时代的到来,为恶性肿瘤包括胆道系统恶性肿瘤治疗提供了令人鼓舞的前景。以免疫检查点抑制剂为基础的联合化疗和/或靶向治疗已经在胆道系统恶性肿瘤治疗中显现良好的效果,是未来晚期胆道系统恶性肿瘤治疗的方向。Biliary malignant tumors have an insidious onset and rapid development,and most patients have lost the opportunity for radical surgery at initial diagnosis and often have poor prognosis.Gemcitabine-based chemotherapy is the first-line treatment for biliary malignant tumors,but with a limited clinical effect.The improvement in next-generation sequencing technology provides the possibility for the precise treatment of biliary malignant tumors,but the application and development of the precise treatment of biliary malignant tumors are limited by the low positive rate of targets and the poor accessibility of therapeutic drugs.The advent of the era of immunotherapy represented by the immune checkpoint inhibitor PD1/PD-L1 monoclonal antibody brings a promising future for the treatment of malignant tumors,including biliary malignant tumors.Combined chemotherapy and/or targeted therapy based on immune checkpoint inhibitors has shown a good effect in the treatment of biliary malignant tumors,which is the direction of the treatment of advanced biliary malignant tumors in the future.

关 键 词：胆道肿瘤 药物疗法 联合 分子靶向治疗 免疫抑制剂 

分 类 号：R73[医药卫生—肿瘤]